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AbstrAct
Objectives We aimed to describe the rate and 
determinants of carotid plaque progression and the onset 
of clinical cardiovascular disease (CVD) in a UK SLE cohort.
Methods Female patients with SLE of white British 
ancestry were recruited from clinics in the North-West 
of England and had a baseline clinical and CVD risk 
assessment including measurement of carotid intima–
media thickness (CIMT) and plaque using B-mode Doppler 
ultrasound. Patients were followed up (>3.5 years after 
baseline visit) and had a repeat carotid Doppler to assess 
progression of plaque and CIMT. Clinical CVD events 
between visits were also noted.
Results Of 200 patients with a baseline scan, 124 (62%) 
patients had a second assessment at a median (IQR) of 
5.8 (5.2–6.3) years follow-up. New plaque developed 
in 32 (26%) (4.5% per annum) patients and plaque 
progression was observed in 52 (41%) patients. Factors 
associated with plaque progression were older age (OR 
1.13; 95%  CI 1.06 to 1.20), anticardiolipin (OR 3.36; 1.27 
to 10.40) and anti-Ro (OR 0.31; 0.11 to 0.86) antibodies. 
CVD events occurred in 7.2% over 5.8 years compared 
with 1.0% predicted using the Framingham risk score 
(p<0.001). Higher triglycerides (OR 3.6; 1.23 to 10.56), 
cyclophosphamide exposure ‘ever’ (OR 16.7; 1.46 to 63.5) 
and baseline Systemic Lupus International Collaborating 
Clinics damage index score (OR 9.62; 1.46 to 123) 
independently predicted future CVD events.
Conclusion Accelerated atherosclerosis remains a 
major challenge in SLE disease management. A more 
comprehensive approach to CVD risk management 
taking into account disease factors such as severity 
and anticardiolipin antibody status may be necessary to 
improve CVD outcomes in this high-risk population.
IntROduCtIOn
The impact of accelerated atherosclerosis on 
morbidity and mortality in SLE has been well 
documented over the past four decades.1 2 
Many questions remain unanswered, particu-
larly relating to risk stratification and factors 
influencing the initiation and progression of 
atherosclerosis. While it is clear that traditional 
cardiovascular disease (CVD) risk factors 
play an important role,3 several studies have 
demonstrated that disease-specific factors are 
also important and as a result, traditional risk 
prediction models perform poorly in SLE.4 
The exact contribution of inflammatory 
burden, renal disease and a procoagulant state 
in the context of long-term corticosteroid and 
immunosuppressant therapy can be difficult 
to evaluate. Studying clinical complications 
alone requires large long-term studies and 
therefore only a few studies have attempted 
to study predictors of actual atherosclerotic 
events in SLE.3 5–7 Several modalities have 
been used to measure subclinical atheroscle-
rosis in SLE and approximately 30%–40% of 
patients have evidence of subclinical lesions 
by a range of methods.8–10 High-resolution 
B-mode Doppler ultrasound has been widely 
used to measure both carotid intima–media 
thickness (CIMT) and carotid plaque. Large 
general population studies have used CIMT 
and found an association with classic cardi-
ovascular risk factors such as hypertension, 
hyperlipidaemia and family history of coro-
nary heart disease (CHD)11–13 and also demon-
strated CIMT to be an independent predictor 
of CHD.14 15 Within SLE, we and others have 
found carotid plaque in 29%–37% of patients 
compared with 15%–22% of controls.16 The 
excess of carotid plaque in SLE is particularly 
striking in those under 55 years old.16 17 There 
are only a few follow-up studies in patients 
with SLE, but these have shown progression 
of carotid plaque, which in turn predicted 
future CVD events.18 19 Factors that have been 
associated with plaque progression in SLE 
included homocysteine, higher C3 comple-
ment and immunosuppressive use.18 19 The 
aim of this study was to describe the rate 
and determinants of carotid atherosclerosis 
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Table 1 Description of 200 patients with SLE at the 
baseline study
Baseline factor 
Age at diagnosis: mean (SD) years 36.4 (11.8)
Disease duration: mean (SD) years 11.7 (9.4)
Previous cerebrovascular event: n (%) 16 (8)
Previous coronary event: n (%) 7 (3.5)
Peripheral vascular disease: n (%) 1 (0.5)
Ever ANA positive: n (%) 188 (94)
Ever dsDNA positive: n (%) 115 (57.5)
Ever aCL or LAC positive: n (%) 73 (37)
Antiphospholipid syndrome: n (%) 21 (10.5)
Current steroid therapy: n (%) 106 (53)
SLEDAI-2K: median (IQR) 1 (0–4)
SLICC damage index: median (IQR) 0 (0–4)
Current antimalarial therapy: n (%) 105 (52.5)
Current immunosuppressive therapy: n 
(%)
74 (37)
Postmenopausal: n (%) 94 (47)
Current smoker: n (%) 40 (20)
Ex-smoker: n (%) 57 (28.5)
Family history of premature CHD: n (%) 53 (26.5)
Total cholesterol: median (IQR) mmol/L 5.1 (4.3–6.0)
Fasting plasma glucose: median (IQR) 
mmol/L
4.6 (4.3–4.9)
Systolic blood pressure: median (IQR) 
mm Hg
126 (116–140)
Previous or current hypertension: n (%) 83 (41.5)
Diabetes (%) 6 (3.0)
BMI: median (IQR) kg/m2 26.0 (23.2–30.1)
Hypertension: blood pressure of >140/90 or current treatment with 
antihypertensive drug. Hypercholesterolemia: total cholesterol 
>5.2 mmol/L or LDL cholesterol >3.2 mmol/L or on therapy. Family 
history of premature CVD: MI, angina or sudden death in a first-
degree relative male <55 years or female <65 years. Diabetes 
mellitus: fasting plasma glucose >7.0 mmol/L or current diabetic 
therapy.
aCL, anticardiolipin antibody; BMI, Body Mass Index; CHD, 
coronary heart disease; CVD, cardiovascular disease; LAC, lupus 
anticoagulant; MI, myocardial infarction; SLEDAI, Systemic Lupus 
Erythematosus Disease Activity Index; SLICC, Systemic Lupus 
International Collaborating Clinics.
progression and the development of clinical CVD events 
in a UK SLE cohort.
MethOds
Our baseline cohort was assembled between 2002 and 
2005 as previously described.16 This cohort was re-con-
tacted and invited back for a further assessment at a 
minimum of 3.5 years after their baseline visit. We made 
several attempts to contact patients no longer under 
follow-up in their original clinic and/or who have moved 
address during the interim period. For those who died, 
we noted the cause of death from their clinic records 
and/or after discussion with their primary treating physi-
cian. The cohort consisted of female patients of white 
British ancestry16 who were at least 18 years old and 
fulfilled four or more 1997 American College of Rheu-
matology (ACR) criteria for SLE.20 Patients who fulfilled 
three criteria for SLE in the absence of any alternative 
diagnosis were also included, as previously described.16 
All patients gave written informed consent and the study 
was approved by the Central Manchester Local Research 
Ethics Committee.
At baseline and at follow-up, patients had a clinical 
interview and examination to collect demographic infor-
mation, family history, lifestyle factors, SLE disease status 
as well as information on traditional cardiovascular risk 
factors and CVD events (personal history from patient), 
that is, myocardial infarction, angina, cerebrovascular 
event, transient ischaemic attack (TIA), coronary inter-
vention and peripheral vascular disease. Cardiovascular 
risk factors were defined as previously described (see 
also table 1) In addition, we defined metabolic syndrome 
according to the 2009 definition described in the Joint 
Interim Statement from the International Diabetes 
Federation Task Force on Epidemiology and Prevention 
and interested partners.21
This requires three or more of the following five criteria 
to be present: (1) elevated waist circumference (>80 cm 
for Europid women), (2) elevated triglycerides (≥1.7 
mmol/L), (3) reduced HDL cholesterol (<1.3 mmol/L 
in women), (4) elevated blood pressure (≥130/85 mm 
Hg) or drug therapy for hypertension, and (5) elevated 
fasting glucose (≥5.6 mmol/L) or drug therapy for 
hyperglycaemia.21
We also collected information on SLE features and 
disease activity (Systemic Lupus Erythematosus Disease 
Activity Index - SLEDAI 2000 edition—SLEDAI-2K)22 and 
damage (ACR/Systemic Lupus International Collabo-
rating Clinics damage index—SDI23). We defined ‘renal 
disease’ as having any one or more of persistent protein-
uria (>500 mg/day), otherwise unexplained microscopic 
haematuria, chronic renal insufficiency, nephrotic 
syndrome or any class of lupus nephritis diagnosed on 
biopsy. Details of current and previous SLE therapy as 
well as other current medications were recorded. Steroid 
exposure was documented as any previous exposure, 
average daily dose (mg/day over the past 6 months), and 
duration of current and previous courses. In participants 
with no prior cardiovascular disease, we estimated the 
5-year percentage risk of cardiovascular events using the 
Framingham risk equation.24
Carotid examinations were undertaken by one of two 
vascular technicians on the day of the clinical assessments, 
one of whom had performed the original scans but both 
were blinded to the baseline carotid examination results 
at time of the follow-up scan. CIMT and plaque were 
quantified as previously described.16 Briefly, the right 
and left common carotid artery (CCA), carotid bulb 
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and the first 1.5 cm of the internal and external carotid 
arteries were examined in longitudinal and cross-sec-
tional planes using the Philips HDI 5000. Intima–media 
thickness (IMT) was measured as previously described 
and validated.25 Measurements were made at the time of 
scanning, in a longitudinal plane at a point of maximum 
thickness on the far wall of the CCA along a 1 cm section 
of the artery proximal to the carotid bulb. Measurements 
were repeated three times on each side, unfreezing the 
image on each occasion and relocating the maximal IMT, 
and the average of six measurements were then used to 
calculate the mean IMT. Carotid plaque was defined if two 
of the following three conditions were met: (1) a distinct 
area of protrusion >50% compared with the surrounding 
area into the vessel lumen, (2) increased echogenicity 
than the adjacent boundaries and (3) IMT >0.15 cm 26 
. Plaque burden was estimated using the plaque index, 
a summary score of number and size of plaque as previ-
ously described.25 A good level of agreement was observed 
between technicians (mean difference −0.001, 95% limits 
of agreement −0.0098 to 0.0078).
All data were analysed using STATA V.13.1 statis-
tical software. Comparisons were made by means of a 
two-sample t-test for normally distributed continuous 
variables and by χ2 analysis for categorical variables. For 
non-normally distributed variables, non-parametric tests 
were determined using Kruskal-Wallis rank test for cate-
gorical variables and Spearman’s correlation coefficients 
for continuous variables. Two-sided p values of less than 
0.05 were considered to be significant. Age-adjusted linear 
and logistic regression analyses were used to determine 
the association between baseline risk factors and progres-
sion in CIMT, carotid plaque and incident clinical cardio-
vascular events. Standardised coefficients were used to 
assess the strength of associations between variables. A 
backward stepwise multivariable model which included 
baseline age, follow-up period and variables that had a 
significant relationship in the univariate analysis or could 
logically be a confounder was performed with a threshold 
for significance at p value <0.2 to assess the best models 
to predict plaque progression (defined as increase in 
plaque index including those with no plaque at baseline 
who developed plaque), CIMT progression and clinical 
CVD events.
Results
Two hundred patients were assessed at baseline and 124 
(62%) were contactable and agreed to return for assess-
ment at a second timepoint. The median (IQR) time 
between visits for these 124 patients was 5.8 (5.2–6.3) 
years. The median (IQR) baseline age and disease dura-
tion was 49 (44–56) and 11 (4–18) years, respectively. Base-
line clinical and serological features of those followed or 
lost to follow-up are summarised in table 2.16 Seventy-six 
(38%) of the baseline cohort did not participate in the 
follow-up study. Forty-five (23%) patients had a change of 
address or could not be contacted; 21 (10.5%) declined 
further participation and of these, one had developed 
throat cancer, one had bladder cancer and another had 
a stroke; the others declined for social reasons (caring 
for relatives, child care and employment). Ten patients 
(5%) died during the follow-up period; causes of death 
included malignancy (four in total; cervical, intracerebral, 
lung and liver), ruptured aortic aneurysm (n=1), cerebral 
haemorrhage (n=1) and gastrointestinal haemorrhage 
(n=1). The cause of death was unknown in three patients. 
Apart from higher triglycerides and lower systolic blood 
pressure at baseline, those who did not return did not 
differ significantly with respect to SLE features, therapy 
exposures or classic CVD risk factors to those who had a 
return visit (table 1).
Progression of carotid atherosclerosis
Table 3 summarises changes in carotid plaque and CIMT 
over time. At baseline, 34/124 (27%) patients had at 
least one carotid plaque and by follow-up, 63/124 (50%) 
patients had at least one plaque. The change in carotid 
plaque status is summarised in figure 1. Almost half of 
patients (59/124; 47.6%) had no plaque at either time 
point. Thirty-two patients (26%) free of plaque at base-
line developed a new plaque at the second assessment. 
Of those with plaque at baseline, 20 (17.5%) had an 
increased plaque index, 9 (7%) patients had a stable 
plaque index over time and 4 (3.2%) had a lower plaque 
index at the follow-up assessment. Fifty-two (41%) 
patients had evidence of plaque progression, defined as 
either new plaque or increase in plaque index.
CIMT overall showed progression between visits 
(table 3); however, we noted that eight (7%) patients had 
regression of CIMT at follow-up.
In univariable analysis, baseline age was associated with 
both plaque and CIMT progression and therefore all anal-
yses were adjusted for age and disease duration. Factors 
associated with plaque progression are summarised in 
table 4. The percentage of 5-year cardiovascular risk at 
baseline was significantly associated with plaque progres-
sion even after adjustment for disease duration (OR 
1.51; 95% CI 1.11 to 2.05). Of note, positive Ro and La 
antibodies were both negatively associated with plaque 
progression (OR 0.27; 0.10 to 0.75 and OR 0.31; 0.11 to 
0.86, respectively). In contrast, anticardiolipin (aCL) anti-
body status was associated with an increased risk of plaque 
progression (OR 3.64; 1.27 to 10.40). In a multivariable 
analysis, a positive aCL remained independently associ-
ated with plaque progression (OR 3.14; 1.10 to 9.01), and 
this was robust when we retained classic risk factors in the 
model (OR 3.57; 1.23 to 10.56).
In a multivariable analysis, lower systolic blood pres-
sure, lower triglycerides and metabolic syndrome all 
remained independently associated with CIMT progres-
sion (table 5).
Clinical outcomes
Twelve (9.7%) patients had 13 CVD events between visits 
(one patient had both a cerebral and coronary event) 
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Table 2 Baseline features of patients with SLE followed up compared with patients with SLE lost to follow-up (p>0.05 
deemed non-significant (NS)) and characteristics at follow-up
Cohort characteristics
At baseline
Patients with 
SLE followed up
N=124
Patients with SLE 
lost to follow-up
N=76
Patients with 
SLE followed up
N=124 P values
Age: median (IQR) years 45 (37–54) 49 (44–57) NS 55 (50–62)
Disease duration: median (IQR) years 7 (4–15) 11 (4–18) NS 17 (10–25)
Total cholesterol: mean (SD) mmol/L 5.3 (1.4) 5.1 (1.1) NS 4.49 (1.96)
HDL cholesterol: mean (SD) mmol/L 1.68 (0.54) 1.65 (0.47) NS 1.58 (1.43)
LDL cholesterol: mean (SD) mmol/L 2.70 (1.21) 2.76 (0.87) NS 3.12 (1.13)
Triglyceride levels: mean (SD) mmol/L 1.37 (0.09) 1.16 (0.57) 0.01 1.18 (0.60)
Systolic blood pressure: mean (SD) mm Hg 125 (19) 132 (19) 0.03 131 (20.1)
Hypertension (%) 29 32 NS 41
Metabolic syndrome (%) 30.1 30.6 NS –
Fasting glucose: mean (SD) mmol/L 4.7 (0.87) 4.6 (0.77) NS 4.6 (0.85)
Smoking ever (%) 54 45 NS 45
Cardiovascular disease (%) 14 9.7 NS 16
Family history of CHD (%) 28 26 NS 26
Body Mass Index (kg/m2): mean (SD) 27 (6) 27 (6) NS 28 (5.8)
Renal disease (%) 21.1 13 NS 18
SDI: median (IQR) 0 (0–2) 0 (0–1) NS 1 (0–2)
SLEDAI: median (IQR) 0 (0–3) 1 (0–4) NS 1 (0–4)
Anticardiolipin antibody positive (%) 28 32 NS
Ro antibody positive (%) 34.2 37.1 NS
La antibody positive (%) 10.9 17.7 NS
DsDNA antibody positive (%) 59. 56 NS
Antimalarial therapy (%) 77 86. NS
Cyclophosphamide therapy (%) 18 10 NS
CHD, coronary heart disease; SDI, Systemic Lupus International Collaborating Clinics damage index; SLEDAI.
Table 3 Rate of carotid intima–media thickness (CIMT) and 
plaque progression in SLE
Follow-up time: mean (SD) years 5.72 (0.89)
Baseline plaque prevalence 345/124 (28%)
Follow-up plaque prevalence 63/124 (50%)
New plaque onset 32/124 (26%)
Plaque change/year 4.5%
Baseline CIMT: median (IQR) cm 0.05 (0.04–0.06)
Follow-up CIMT: median (IQR) cm 0.06 (0.05, 0.07)
CIMT change/year: mean (SD) cm/year 0.002 (0.001)
(table 6). Of the 12 (9.7%) patients with known clinical 
CVD at baseline, 4 (33%) had a further event. In those free 
of CVD at baseline (n=112), the new event rate was 7.2% 
(eight patients) over 5.8 years. In contrast, the median 
predicted 5-year percentage risk for this cohort was 1 
(1–3)% (p<0.001). The median (IQR) 5-year percentage 
risk tended to be higher in those with a future CVD event 
(2.5 (1.5–5)% vs 1 (1–3)%, p=0.12).
Predictors of clinical CVd events
In an age-adjusted univariable analysis (table 4), a number 
of classic risk factors and SLE-related factors were associ-
ated with future CVD events. Neither presence of carotid 
plaque nor CIMT at baseline predicted future events 
(date on file). In a multivariable analysis, higher triglyc-
erides (OR 3.61; 1.23 to 10.56), cyclophosphamide expo-
sure ‘ever’ (OR 16.7; 1.46 to 63.5) and the SDI score (OR 
9.62; 1.46 to 123) independently predicted CVD events 
(table 7). When we removed the CVD descriptors from 
the SDI, it remained in the model (OR 9.89; 1.51 to 64.4).
dIsCussIOn
In this longitudinal study of white British women with 
SLE, we found over a median 5.8 years of follow-up, 
26% developed new carotid plaque and carotid plaque 
progressed overall in 41%. In addition, 7.2% of those free 
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Figure 1 Summary of plaque at follow-up.
of CVD at baseline had a new CVD event in this period, a 
sevenfold higher rate than predicted by the Framingham 
model.
Our data accord with the Hopkins Cohort study 
in which new carotid plaque was observed in 26% of 
patients, and at the second assessment, a higher plaque 
index was observed in another 17.5%.27 In a general 
population-based study of women aged 59–71 years, 
carotid plaque progressed in 18% over 4 years.28 There-
fore, our findings and those of Kiani et al suggest that 
carotid plaque progresses at a higher rate in patients with 
SLE than would be expected.27 Our overall carotid plaque 
progression rate (4.5% per annum) is in agreement with 
that estimated by Thompson et al in Pittsburgh (6.5% per 
annum). In addition, like us, Thompson et al noted only 
minimal plaque regression (5%).29 As expected, age is a 
key determinant of new plaque development. Interest-
ingly, we found that of SLE features, anti-Ro antibody was 
associated with reduced risk of new plaque and aCL anti-
bodies were associated with greater plaque progression. 
The association with aCL antibodies remained significant 
in both a multivariable model and in a model including 
classical risk factors. We defined aCL antibodies as the 
presence of two positive results at a moderate to high titre 
at any time during the disease duration. Our previous 
study had found a cross-sectional association between 
aCL and prevalent plaque.16 Our current results suggest 
this association was with atherogenesis and may reflect the 
presence of cross-reacting epitopes with our clinical assay 
that are pro-atherogenic. Previous work has suggested 
that certain autoantibody subtypes such as anti-HDL or 
anti-oxLDL antibodies may be associated with aCL and 
be in themselves atherogenic.30 Ro-positive patients may 
represent a phenotypic subset with a lower risk of athero-
sclerosis, although the precise mechanism(s) underlying 
this cannot be ascertained from this study.
The mean change in CIMT in our cohort (0.002 
cm/year) is in the range reported in other SLE studies 
(0.0012–0.0039 cm/year).31–33 This is approximately 
double the rate previously reported in the general popula-
tion.34 In contrast, a recent controlled study has suggested 
that CIMT progression in SLE is no greater than a control 
population.32 In the current study, univariable factors asso-
ciated with CIMT change were total cholesterol, the meta-
bolic syndrome, SDI and C4 levels. Paradoxically, SDI was 
negatively correlated with CIMT progression suggesting a 
higher SDI correlates with less IMT progression. This may 
be an artefact due to the small sample size of the study, 
given the wide CIs observed. Another possible explana-
tion is a surviving cohort effect, that is, those with higher 
rates of damage accrual have left the cohort at baseline. 
While the baseline SDI was comparable in those who were 
and were not followed, we were unable to assess if those 
who were lost to follow-up accrued further damage after 
their baseline assessment (although we do know that in 
this group at least six developed a new cancer and two 
had major cardiovascular events). Similarly, in the multi-
variable analysis, triglyceride level, systolic blood pressure 
and fasting glucose were negatively correlated with CIMT 
progression. Again, sample size or a surviving cohort 
effect may explain these apparently paradoxical results.
Our study also adds to the observations of others that 
clinical CVD events occur at a higher rate in SLE that 
is predicted by usual risk estimate equations. In this 
study, there was a sevenfold higher rate of cardiovas-
cular events than predicted. In addition, the only tradi-
tional risk factor which significantly predicted events was 
triglyceride levels. Esdaile et al previously noted a seven-
fold higher than predicted rate of events in a cohort of 
patients with SLE4 and Bessant et al also noted that while 
the mean 10-year percentage risk of coronary events in 
their cohort was 1.4 (0.2–3.4)%, over follow-up, 8.5% 
actually had a coronary event.35 With regard to risk 
factors for clinical events, in a longitudinal analysis of 
the Toronto cohort, age and triglyceride levels were the 
only significant predictors of future CVD events. This 
emphasises the need for better risk stratification models 
in patients with SLE. With regard to SLE-related factors, 
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Table 4* Univariable analysis of baseline factors associated with progression of carotid atherosclerosis and clinical 
cardiovascular events (CVEs)
Baseline factors
Plaque progression CIMT progression CVEs
Age-adjusted 
OR 95% CI
Age-adjusted
β (SE) P values
Age-adjusted 
OR 95% CI
Prior CVEs 1.63 0.145 to 18.27 0.0059 (0.0035) 0.69 4.89 1.15 to 20.65
Disease duration (years)* 1.00 0.95 to 1.05 −0.08090 (0.00009) 0.39 1.04 0.97 to 1.09
Total cholesterol (mmol/L)* 0.90 0.617 to 1.31 −0.19442 (0.0008) 0.03 0.93 0.51 to 1.6
Hypercholesterolemia 4.31 0.86 to 21.59 0.07482 (0.00283) 0.46 1.48 0.22 to 5.86
LDL cholesterol (mmol/L)* 0.93 0.58 to 1.60 −0.07829 (2.9×10−4) 0.41 0.61 0.28 to 1.34
Triglycerides (mmol/L)* 1.25 0.61 to 2.55 −0.06203 (2.0×10−4) 0.18 2.92 1.3 to 6.46
Systolic blood pressure (mm Hg)* 1.01 0.99 to 1.05 −0.17274 (0.00005) 0.06 1.038 0.96 to 1.12
Hypertension 1.12 0.43 to 3.23 −0.04238 (0.00203) 0.53 6.19 1.5 to 25.47
Fasting glucose (mmol/L)* 0.72 0.30 to 1.70 −0.10982 (0.00125) 0.19 1.00
Type 2 diabetes 0.63 0.03 to 13.77 −0.01446 (0.00754) 0.10 No events in 
diabetic group
NA
Smoking ever 1.67 0.0.68 to 3.89 0.05302 (0.00191) 0.55 0.64 0.18 to 2.24
Family history of CHD 0.45 0.17 to 1.18 −0.07237 (0.00215) 0.39 1.27 0.34 to 4.7
Body Mass Index* 1.02 0.96 to 1.11 −0.11030 (0.00017) 0.26 1.01 0.93 to 1.14
Metabolic syndrome 1.51 0.53 to 4.30 0.17552 (0.00224) 0.05 2.29 0.67 to 7.77
Renal disease 0.63 0.165 to 2.30 0.06337 (0.00156) 0.52 1.83 0.85 to 3.92
Creatinine (mmol/L)* 0.99 0.99 to 1.00 0.00325 (0.00002) 0.96 0.99 0.99 to 1.00
Prior venous thromboembolism 1.73 0.62 to 4.85 −0.00251 (0.00291) 1.21 4.16 1.08 to 15.9
SDI* 1.28 0.89 to 1.85 −0.18343 (0.00080) 0.04 1.77 1.21 to 19.2
SLEDAI* 0.94 0.77 to 1.14 0.06239 (0.00040) 0.24 1.77 1.15 to 2.62
C3* 1.44 0.0.32 to 6.51 −0.03074 (0.00351) 0.74 2.27 0.23 to 22
C4* 1.02 0.00 to 799.6 −0.17369 (0 .00026) 0.05 1.74 0.5 to 5.95
Ro positive 0.31 0.11 to 0.86 −0.004072 (0.00221) 0.92 1.16 0.34 to 3.98
La positive 0.45 0.13 to 1.57 0.04982 (0.00276) 0.61 1.40 0.34 to 5.88
RNP positive 0.50 0.14 to 2.17 0.05530 (0.00310) 0.46 0.63 0.07 to 5.49
Anticardiolipin antibody positive 3.64 1.27 to 10.40 −0.08619 (0.00206) 0.45 1.46 0.23 to 4.99
Lupus anticoagulant positive 0.93 0.36 to 2.41 −0.002 (1.191) 0.41 2.11 0.35 to 12.44
Antimalarial use 0.37 0.09 to 1.53 −0.12049 (0.00274) 0.19 No events is 
non-use group
Antiplatelet use 0.60 0.23 to 1.59 −0.02194 (0.00208) 0.76 0.97 0.30 to 3.06
Statin use 7.39 0.86 to 63.28 0.05112 (0.00310) 0.76 1.83 0.52 to 6.48
Steroid exposure ever 1.14 0.42 to 3.06 −0.04302 (0.00227) 0.76 1.36 0.35 to 8.2
Average steroid dose (mg)* 1.03 0.95 to 1.12 0.10877 (0.00017) 0.21 1.14 1.03 to 1.26
Total steroid dose (mg)* 1.00 0.99 to 1.00 −0.00175 (1.1×10−4) 0.98 0.99 0.99 to 1.00
Cyclophosphamide ever 1.93 0.44 to 8.43 −0.00134 (0.00319) 0.674 4.2* 1.77 to 35
Azathioprine ever 1.10 0.394 to 3.12 −0.00384 (0 .00204) 0.065 3.30 0.94 to 11.58
Framingham-based 5-year CVD % 
risk (only patients with no prior CVD)*
1.47 1.12 to 1.93 −0.000464 (0.00034) 0.262 1.09 0.88 to 1.35
Items in bold denote significant results on univariate or age-adjusted analyses
Denotes baseline factors analysed as continuous variables.
CHD, coronary heart disease; CIMT, carotid intima–media thickness; CVD, cardiovascular disease; NA, not applicable; RNP, ribonucleoprotein; SDI, 
Systemic Lupus International Collaborating Clinics damage index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
our study was underpowered to assess a range of factors. 
Cyclophosphamide exposure was a strong predictor of 
cardiovascular events at follow-up and remained in the 
multivariable model. While this association could reflect 
unmeasured confounders such as disease severity and 
cumulative steroid burden, the small number of patients 
on cyclophosphamide and wide CIs do mean this result 
should be interpreted with caution. However, the associ-
ation between higher SDI and future CVD events both 
in this study and in a previous case–control study in the 
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Table 5 Multivariable analysis of baseline factors 
associated with progression of carotid intima–media 
thickness (CIMT)
Baseline factors
CIMT progression
β (SE) P values
Systolic blood pressure (per 10 
mm Hg)
−0.00012 (0.00004) 0.004
Fasting glucose (per mmol/L) −0.00148 (0.00095) 0.121
Triglycerides (per mmol/L) −0.00492 (0.00138) 0.001
Metabolic syndrome (yes/no) 0.00473 (0.02102) 0.027
Table 6 Rate of cardiovascular events (CVEs) at follow-up
Patients 
with events
Rate over 5.8 
years
All CVEs 12 9.7
Coronary event 7 5.6
Cerebral events 5 4
Peripheral vascular events 1 0.8
Primary CVE 8 7.2
5-year % Framingham estimate 1.0 (1.0–3.0)%
Table 7 Multivariable analysis of baseline factors 
associated with cardiovascular events (CVEs)
Baseline factors
CVEs
OR 95% CI
Triglycerides (per mmol/L) 3.61 1.23 to 10.56
Cyclophosphamide ever 16.7 1.46 to 123
SDI>0 9.62 1.46 to 63.5
SDI, Systemic Lupus International Collaborating Clinics damage 
index.
UK may support this hypothesis.3 A higher SDI is likely to 
reflect the cumulative burden of chronic inflammation36 
and steroid exposure37 or alternatively, patients prone to 
damage in one organ system may also be more prone to 
atherosclerotic damage.38 Further studies investigating 
these associations are therefore warranted.
It is interesting to note that neither CIMT nor the pres-
ence of plaque at baseline were associated with CVD events 
at follow-up and that different baseline factors predicted 
subclinical and clinical outcomes. Both CIMT and carotid 
plaque have been shown to be predictors of long-term 
cardiovascular mortality in large population studies. Kao 
et al undertook the only published study, which has eval-
uated the association between baseline CIMT and plaque 
with future CV events in SLE.19 In this study of 392 female 
patients with SLE (median follow-up 7.9 years), a border-
line association between CIMT, plaque presence and inci-
dent CV events was observed (OR (95% CI) 1.14 (1.00 
to 1.31) and 1.83 (0.91 to 3.66) for baseline CIMT and 
plaque, respectively). When only ‘hard’ CV events were 
considered (angina or TIA excluded), the association 
became statistically significant. This study had a larger 
sample and followed for longer than the current study. 
Thus, it is likely that we were underpowered to detect 
the association between subclinical disease and subse-
quent clinical events. There is also some debate about 
which measure of plaque progression to use in longitu-
dinal analyses. It should be noted that risk factors for the 
initiation of atherosclerosis may be different to those for 
disease progression or severity. In this regard, the most 
appropriate comparison groups may be those with no 
plaque versus those with new plaque over time. To obtain 
meaningful results, long-term follow-up of a large cohort 
of patients is required. The differences observed in this 
study with regard to CIMT may also reflect the differences 
in measurement as some previous studies have limited 
measurement to one part of the carotid artery.31 Addi-
tionally, unlike previous studies, the current study was 
limited to white British women, as the original cohort was 
set up to study genetic factors. This is a limitation of the 
current study and there is a need to conduct further CVD 
outcome studies in non-Caucasian populations.
A number of other limitations need to be considered 
when interpreting these findings. The sample size in the 
current study of 124 patients is relatively small and while 
the average follow-up period of more than 5 years is longer 
than in previously reported studies, this is still a relatively 
short period of follow-up. The limitations of sample size 
and duration of follow-up in this study may have influ-
enced the ability to detect a correlation between clinical 
events and subclinical measures. Furthermore, the clinical 
events were patient reported, which is a weakness. We also 
acknowledge that our follow-up cohort only included 62% 
of our original group. We made every reasonable effort 
to contact all patients; however, a number were truly lost 
to follow-up, which may be inevitable in a mobile urban 
population. In addition, another large group declined to 
return for study, mainly due to changing of their personal 
circumstances. There is of course the potential for bias 
being introduced. When examining differences in base-
line characteristics of those followed or lost to follow-up, 
lower serum triglyceride levels and higher systolic blood 
pressure were noted in those who were followed up. All 
other CVD risk factors and disease characteristics were 
similar between the groups. Those lost to follow-up did 
not have any consistent markers of a differential level 
of disease severity or CVD risk. However, if those lost to 
follow-up had more severe disease, it would, if anything, 
tend to bias us towards a conservative estimate of clin-
ical and subclinical disease progression. Whether or not 
this is the case, the factors we identified as significant 
predictors will maintain validity within this cohort and 
since our power will be limited by the smaller follow-up 
group, significant results remain of relevance. However, 
we acknowledge that several important factors (eg, anti-
malarial use) may have been identified or confirmed, due 
to limited power.
Longitudinal studies provide the opportunity to deter-
mine factors that will help us improve risk stratification 
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of SLE populations for future CVD events and the iden-
tification of potentially modifiable risk factors. Our 
results suggest that a more comprehensive approach to 
risk stratification is needed as well as classic risk factors, 
for example, triglycerides which are less often a target 
for intervention also contribute to future CVD events in 
SLE. A higher-risk population may also be identified from 
patients who require potent immunosuppression as well 
as those with anticardiolipin antibodies. Such factors may 
be a useful adjunct to routine CVD screening approaches 
and may result in improved CVD risk in this high-risk 
population.
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